Abstract | BACKGROUND & OBJECTIVE:
CHOP regimen is a standard treatment for patients with diffuse large B-cell non-Hodgkin's lymphoma (NHL), and its 5-year overall survival (OS) rate is 30%-40%. Rituximab is a chimeric monoclonal antibody (MoAb) directly against CD20-positive B cells, and has good effect on diffuse large B-cell NHL. Rituximab combined with standard chemotherapy has been approved for treating aggressive B-cell NHL in Europe and the US. This study was to determine efficacy and safety of the combination of Rituximab and CHOP regimen in treating Chinese patients with CD20-positive diffuse large B-cell NHL. METHODS: From Sep. 2003 to Nov. 2004, a total of 63 patients in 9 centers were enrolled. All the patients were randomized into 2 groups: 32 received CHOP regimen alone (CHOP group), and 31 received Rituximab and CHOP regimen (R-CHOP group). All patients signed informed consent. The complete response rates, overall response rates, and side events of the 2 groups were compared. RESULTS: The complete response rates were similar in R-CHOP and CHOP groups (41.9% vs. 37.5%, P=0.719); the overall response rates were slightly higher in R-CHOP group than in CHOP group (83.8% vs. 65.6%, P=0.096). Disease progression during treatment was reported for 7 (21.9%) patients in CHOP group and 1 (3.2%) patient in R-CHOP group (P=0.026). The occurrence rates of adverse events were similar in R-CHOP and CHOP groups (65.6% vs. 67.7%, P=0.859). The most common adverse event was leukopenia; fever and chills were rather common in R-CHOP group. Clinically relevant toxicity was similar in both groups. CONCLUSION: When compared with standard CHOP alone, the addition of Rituximab to standard CHOP regimen reduces the risk of treatment failure in patients with diffuse large B-cell NHL, and doesn't increase the occurrence of chemotherapy-related adverse events.
|
Authors | Tong-Yu Lin, Hong-Yu Zhang, Yan Huang, Zhong-Zhen Guan, Ti Shen, Yuan-Kai Shi, Jun Zhu, Xiao-Yan Ke, Hua-Qing Wang, Zhi-Xiang Shen, Shi-Ying Yu, Ting Liu, Xiao-Li Shi |
Journal | Ai zheng = Aizheng = Chinese journal of cancer
(Ai Zheng)
Vol. 24
Issue 12
Pg. 1421-6
(Dec 2005)
China |
PMID | 16351785
(Publication Type: Comparative Study, English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20
- Antineoplastic Agents
- Rituximab
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisolone
|
Topics |
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal
(administration & dosage, adverse effects)
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20
(metabolism)
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- China
- Cyclophosphamide
(administration & dosage, adverse effects)
- Doxorubicin
(administration & dosage, adverse effects)
- Female
- Humans
- Leukopenia
(chemically induced)
- Lymphoma, B-Cell
(drug therapy, immunology)
- Lymphoma, Large B-Cell, Diffuse
(drug therapy, immunology)
- Male
- Middle Aged
- Prednisolone
(administration & dosage, adverse effects)
- Remission Induction
- Rituximab
- Vincristine
(administration & dosage, adverse effects)
|